Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

NorthWest Healthcare Properties Real Estate Invest 10 Convert Sub Debentures 31 March 2025 T.NWH.DB.H


Primary Symbol: T.NWH.DB.G Alternate Symbol(s):  NWHUF | T.NWH.UN | T.NWH.DB.I

Northwest Healthcare Properties Real Estate Investment Trust is an open-ended real estate investment trust. The Company is the owner and operator of healthcare real estate infrastructure in North America, Brazil, Europe and Australasia. The principal business of the Company is to invest in healthcare real estate globally. It focuses on the cure segment of healthcare real estate, such as hospitals, medical office buildings, and clinics. Its asset class segmentation includes hospitals and healthcare facilities; medical office buildings; and life sciences, research, and education. It provides investors with access to a portfolio of international healthcare real estate infrastructure of interests in a diversified portfolio of about 196 income-producing properties located throughout major markets in North America, Brazil, Europe and Australasia. Its portfolio of medical office buildings, clinics, and hospitals is characterized by long-term indexed leases and stable occupancies.


TSX:NWH.DB.G - Post by User

Post by incomedreamer11on Nov 19, 2024 8:48am
174 Views
Post# 36319433

Scotia comments after conference

Scotia comments after conference

Dare We Say - The Worst Is Behind Us

OUR TAKE: We think NWH can reclaim five handle on the stock. Six when we see clarity on CEO transition.

Cut to half: 2022, 2023 and 2024E delivered double-digits AFFOPU y/y declines (Exhibit 7) with cumulative total of 55% decline (earnings cut to half). Look at Interest Expense as % of NOI (Exhibit 3): as interest rates increased in mid-2022, Interest as % of NOI ballooned to more than half of NOI versus only one-third previously. Q2/25 will be the first quarter in almost three years, when AFFOPU is likely to show positive y/y growth (interest burden normalizing).

Yield is for real: Distribution yield is 7.4% and AFFO payout ratio normalizes to 80% in 2025 vs over 100% last year (Exhibit 2). Only name in our coverage with 7%+ yield and 80% or less payout ratio.

Handicap NAV discount: Scotia NAV at $6.50 (-$0.25) as NWH trading at ~25% discount to NAV. We see narrowing of NAV discount as 2025 debt maturities largely dealt with. For stock to trade closer to our NAV, market needs to be comfortable that new CEO will continue the turnaround (search process underway, current CEO until end of June 2025).

KEY POINTS

2025E AFFOPU estimates slightly reduced but still seen as a big recovery: Post in line Q3 results (details on page 6), our 2024E AFFOPU is reduced by 4% and our 2025 reduced by 8%. We see 17% y/y growth in 2025 and 10% y/y growth in 2026. UK portfolio sale was accretive to earnings (link to our previous note). While we don’t model incremental dispositions in our model, we suspect Brazil portfolio with IFRS value of $670M could be a disposition candidate (either some assets or outright). NWH has reduced its workforce by 16% and recorded one-time $3.8M of termination benefits costs, which will contribute $3.7M of annualized savings. We $15M of quarterly G&A expense, but see some downside to this number. Our 2025E AFFOPU estimate decreased mainly due to reduced NOI assumptions and increase in interest expense estimates.

Debt refinancing risk has significantly reduced (Exhibit 9) but leverage is still elevated: Only 14% (27% as of Q2) of total debt matures in 2025 vs 42% at the start of the year. $1.1B of total debt repaid, refinanced or extended since Q2/24. $735M of total debt repaid with 2024/2025 maturities, at an average rate of 7.64%. See our recent note titled 2025 Debt Maturities Largely Tackled for details. Now, $345M of debt maturing in 2025 - this includes $220M of property level debt which will be done in the normal course. Also, $125M of Converts which NWH intends to repay on maturity in March through proceeds from asset sales (including Assura PLC share sales).Balance sheet: Reduction in leverage as D/GBV (including Converts) at 57.3% as of Q3 which was down 320bp q/q. Leverage is still elevated and still a lot of wood to chop. For stock to trade at our NAV ($6.50) or closer to IFRS NAV ($9.00), we need another large portfolio disposition (ideally Brazil and some US properties).

Valuation: NWH trades at 10.9x 2025E AFFO multiple, ~25% discount to our NAV, and 7.5% implied cap rate. NWH valuation looks reasonable in the context of higher leverage and higher payout ratio – Exhibit 1. NWH distribution yield is 7.4% and our revised 2024E AFFO payout ratio is 94% and should normalize to 80% in 2025.


<< Previous
Bullboard Posts
Next >>